Experts question push for 'abuse-deterrent' Rx opioids

June 1, 2017 by Ziba Kashef
Experts question push for ‘abuse-deterrent’ Rx opioids
Credit: Yale University

In response to the rise in opioid overdose deaths nationwide, pharmaceutical companies have developed formulations of prescription opioids designed to prevent tampering or abuse. These "abuse-deterrent" forms, however, are expensive and may not actually have the intended effect, say experts from Yale School of Medicine.

In a Perspective piece published in the New England Journal of Medicine (NEJM), Drs. William Becker and David Fiellin explore the potential pitfalls and benefits of moving toward greater prescribing of abuse-deterrent opioids. This approach, they said, may distract physicians from the goal—stated by the Centers for Disease Control and Prevention—of pursuing alternatives to opioids to treat pain, especially long-term. These alternatives include evidence-based treatments like , structured exercise programs, yoga, and , they said.

Taking opioids at a higher dose than prescribed is the most common way the drugs are misused. But the abuse-deterrent formulations, which include extended release pills and gels that are difficult to inject, don't prevent patients from taking higher-than-prescribed doses, the authors noted. Additionally, the new formulations do not address the many adverse effects of taking opioids, which include a higher risk of death from using the drugs long-term.

As physicians and policymakers wrestle with how to reduce overdose deaths, Becker and Fiellin encourage them to expand access to addiction treatment and focus on the evidence, which fails to show benefit for many patients from long-term use of opioids—abuse-deterrent or not.

"Unfortunately, the hope that long-term opioid therapy would be effective for chronic pain has not borne out," said Becker. "Expensive endeavors to make 'abuse-deterrent' formulations are not what the field and, most importantly, patients need."

Explore further: FDA: Draft guidance issued on abuse-deterrent opioids

More information: William C. Becker et al. Abuse-Deterrent Opioid Formulations—Putting the Potential Benefits into Perspective, New England Journal of Medicine (2017). DOI: 10.1056/NEJMp1701553

Related Stories

FDA: Draft guidance issued on abuse-deterrent opioids

January 10, 2013
(HealthDay)—The U.S. Food and Drug Administration has issued a draft guidance document to assist the pharmaceutical industry in developing new formulations of opioid drugs with abuse-deterrent properties.

Opioid dependence can start in just a few days

March 16, 2017
(HealthDay)—Doctors who limit the supply of opioids they prescribe to three days or less may help patients avoid the dangers of dependence and addiction, a new study suggests.

FDA outlines standards for anti-abuse generic painkillers (Update)

March 24, 2016
Federal officials are encouraging generic drugmakers to develop painkillers that are harder to abuse, the latest in a string of steps designed to combat abuse of highly-addictive pain drugs like codeine and oxycodone.

Pharmacist prescribes education as key to curbing opioid abuse

May 27, 2016
Technologies that make it harder for people to abuse opioids - like doctoring pills so that they produce unpleasant side effects if broken, crushed or injected—likely will have limited effectiveness in stemming the global ...

Physical therapy is best choice for pain management

August 29, 2016
According to the Centers for Disease Control and Prevention (CDC), sales of prescription opioids have quadrupled in the United States since 1999, even though there has not been an overall change in the amount of pain reported.

7 in 10 U.S. workplaces hit by opioid abuse: survey

March 11, 2017
(HealthDay)—Prescription drug abuse has seeped into the American workplace, with 70 percent of businesses saying it affects their workers, a new survey reveals.

Recommended for you

Fighting opioid addiction in primary care—new study shows it's possible

October 18, 2017
For many of the 2 million Americans addicted to opioids, getting good treatment and getting off prescription painkillers or heroin may seem like a far-off dream.

With no morphine, 25 million die in pain each year: report

October 13, 2017
Every year, some 25 million people—one in ten of them children—die in serious pain that could have been alleviated with morphine at just a few cents per dose, researchers said Friday.

Study finds few restrictions on Rx opioids through Medicare

October 9, 2017
Medicare plans place few restrictions on the coverage of prescription opioids, despite federal guidelines recommending such restrictions, a new Yale study finds. The research results highlight an untapped opportunity for ...

Nocebo effect: Does a drug's high price tag cause its own side effects?

October 5, 2017
Pricey drugs may make people more vulnerable to perceiving side effects, a new study suggests—and the phenomenon is not just "in their heads."

Pre-packaged brand version of compounded medication to prevent preterm births costs 5,000 percent more

October 2, 2017
Preventing a preterm birth could cost as little as $200 or as much as $20,000, depending on which one of two medications a doctor orders, according to a new analysis from Harvard Medical School.

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

BackBurner
not rated yet Jun 07, 2017
This is just nonsense. The media is confounding street drug use with prescribed use. It's absurd.

As a chronic pain sufferer and long term user of opiate analgesics, I can say with certainty that no one prescribed these drugs intentionally abuses them. Period. We're extremely careful.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.